{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:35:40Z","timestamp":1787726140257,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00428-021-03110-9","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T13:32:51Z","timestamp":1620048771000},"page":"755-764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis"],"prefix":"10.1007","volume":"479","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8727-4615","authenticated-orcid":false,"given":"Alexandre","family":"Guy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Bidet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charline","family":"Caumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Boureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Viallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Parrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"3110_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic J-P, Staerk J, Delhommeau F, Lacout C, Gar\u00e7on L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu S, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemiavera. Nature 434:1144\u20131148. https:\/\/doi.org\/10.1038\/nature03546","journal-title":"Nature"},{"key":"3110_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly BJP, Boggon TJ, Wlodarska I, Clark J, Moore S, Adelsperger J, Koo S, Lee J, Gabriel S, Mercher T, D\u2019Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa R, Tefferi A, Griffin J, Eck M, Sellers W, Meyerson M, Golub T, Lee S, Gilliland D (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397. https:\/\/doi.org\/10.1016\/j.ccr.2005.03.023","journal-title":"Cancer Cell"},{"key":"3110_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou G, Bench A, Boyd E, Curtin N, Scott M, Erber W, Green A (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061. https:\/\/doi.org\/10.1016\/S0140-6736(05)71142-9","journal-title":"Lancet"},{"key":"3110_CR4","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Passweg J, Tichelli A, Cazzola M, Skoda R (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790. https:\/\/doi.org\/10.1056\/NEJMoa051113","journal-title":"N Engl J Med"},{"key":"3110_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Azezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincoren I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O\u2019Meara S, McLaren S, Bianchi M, Silver Y, Dimitropoulou D, Bloxhan D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du M-Q, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa1312542","journal-title":"N Engl J Med"},{"key":"3110_CR6","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Carola CasettiSant\u2019Antonio IE, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Sch\u00f6negger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379\u20132390. https:\/\/doi.org\/10.1056\/NEJMoa1311347","journal-title":"N Engl J Med"},{"key":"3110_CR7","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert B, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark J, Lee S, Golub T, Wadleigh M, Gilliland D, Levine R (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270. https:\/\/doi.org\/10.1371\/journal.pmed.0030270","journal-title":"PLoS Med"},{"key":"3110_CR8","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108:3472\u20133476. https:\/\/doi.org\/10.1182\/blood-2006-04-018879","journal-title":"Blood"},{"key":"3110_CR9","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123:2220\u20132228. https:\/\/doi.org\/10.1182\/blood-2013-11-537167","journal-title":"Blood"},{"key":"3110_CR10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.24978","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Mannarelli C, Fanelli T, Guglielmelli P, Vannucchi A (2018) Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol 93:348\u2013355. https:\/\/doi.org\/10.1002\/ajh.24978","journal-title":"Am J Hematol"},{"key":"3110_CR11","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Mass\u00e9 A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, L\u00e9cluse Y, Plo I, Dreyfus F, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguie\u0301 F, Fontenay M, Vainchenker V, Bernard O (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289\u20132301","journal-title":"N Engl J Med"},{"key":"3110_CR12","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","volume":"110","author":"SO Ciurea","year":"2007","unstructured":"Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W, Bruno E, Barosi G, Xu M, Hoffman R (2007) Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 110:986\u2013993. https:\/\/doi.org\/10.1182\/blood-2006-12-064626","journal-title":"Blood"},{"key":"3110_CR13","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","volume":"113","author":"RA Mesa","year":"2009","unstructured":"Mesa RA (2009) How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 113:5394\u20135400. https:\/\/doi.org\/10.1182\/blood-2009-02-195974","journal-title":"Blood"},{"key":"3110_CR14","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","volume":"112","author":"J-J Lataillade","year":"2008","unstructured":"Lataillade J-J, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, Martyr\u00e9 MC, Le Bousse-Kerdil\u00e8s MC (2008) Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 112:3026\u20133035. https:\/\/doi.org\/10.1182\/blood-2008-06-158386","journal-title":"Blood"},{"key":"3110_CR15","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1158\/0008-5472.CAN-09-3977","volume":"70","author":"SY Cho","year":"2010","unstructured":"Cho SY, Xu M, Roboz J, Lu M, Mascarenhas J, Hoffman R (2010) The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res 70:3402\u20133410. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3977","journal-title":"Cancer Res"},{"key":"3110_CR16","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/modpathol.3800480","volume":"18","author":"DP O\u2019Malley","year":"2005","unstructured":"O\u2019Malley DP, Kim YS, Perkins SL, Baldridge L, Juliar BE, Orazi A (2005) Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders. Mod Pathol 18:1550\u20131561. https:\/\/doi.org\/10.1038\/modpathol.3800480","journal-title":"Mod Pathol"},{"key":"3110_CR17","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.humpath.2007.04.004","volume":"38","author":"S Konoplev","year":"2007","unstructured":"Konoplev S, Hsieh P-P, Chang C-C, Medeiros L, Lin P (2007) Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis. Hum Pathol 38:1760\u20131763. https:\/\/doi.org\/10.1016\/j.humpath.2007.04.004","journal-title":"Hum Pathol"},{"key":"3110_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/modpathol.3800826","volume":"20","author":"P-P Hsieh","year":"2007","unstructured":"Hsieh P-P, Olsen RJ, O\u2019Malley DP, Konoplev S, Hussong J, Dunphy C, Perkins SL, Cheng L, Lin P, Chang C (2007) The role of Janus kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. Mod Pathol 20:929\u2013935. https:\/\/doi.org\/10.1038\/modpathol.3800826","journal-title":"Mod Pathol"},{"key":"3110_CR19","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1182\/blood.V97.11.3665","volume":"97","author":"RA Mesa","year":"2001","unstructured":"Mesa RA (2001) Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood 97:3665\u20133667. https:\/\/doi.org\/10.1182\/blood.V97.11.3665","journal-title":"Blood"},{"key":"3110_CR20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/modpathol.2012.33","volume":"25","author":"S Prakash","year":"2012","unstructured":"Prakash S, Hoffman R, Barouk S, Wang Y, Knowles D, Orazi A (2012) Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. Mod Pathol 25:815\u2013827. https:\/\/doi.org\/10.1038\/modpathol.2012.33","journal-title":"Mod Pathol"},{"key":"3110_CR21","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.3324\/haematol.2018.193763","volume":"103","author":"E Zimran","year":"2018","unstructured":"Zimran E, Tripodi J, Rampal R, Rappoport F, Zirkiev S, Hoffman R, Najfeld V (2018) Genomic characterization of spleens in patients with myelofibrosis. Haematologica 103:e446\u2013e449. https:\/\/doi.org\/10.3324\/haematol.2018.193763","journal-title":"Haematologica"},{"key":"3110_CR22","unstructured":"World Health Organization (WHO) Classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. Available at: https:\/\/apps.who.int\/bookorders\/anglais\/detart1.jsp?codlan=1&codcol=70&codcch=24002. Accessed 11 May 2020"},{"key":"3110_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","volume":"136","author":"TS Larsen","year":"2007","unstructured":"Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N (2007) The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 136:745\u2013751. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06497.x","journal-title":"Br J Haematol"},{"key":"3110_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jmoldx.2015.07.007","volume":"18","author":"O Mansier","year":"2016","unstructured":"Mansier O, Migeon M, Saint-L\u00e9zer A, James C, Verger E, Robin M, Soci\u00e9 G, Bidet A, Mahon FX, Cassinat B, Lippert E (2016) Quantification of the mutant CALR allelic burden by digital PCR. J Mol Diagn 18:68\u201374. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.07.007","journal-title":"J Mol Diagn"},{"key":"3110_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","volume":"149","author":"EM Boyd","year":"2010","unstructured":"Boyd EM, Bench AJ, Goday-Fern\u00e1ndez A, Anand S, Vaghela K, Beer P, Scott M, Bareford D, Green AR, Huntly B, Erber W (2010) Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 149:250\u2013257. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08083.x","journal-title":"Br J Haematol"},{"key":"3110_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/gcc.21960","volume":"51","author":"M Brecqueville","year":"2012","unstructured":"Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci M-J, Birnbaum D, Murati A (2012) Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 51:743\u2013755. https:\/\/doi.org\/10.1002\/gcc.21960","journal-title":"Genes Chromosomes Cancer"},{"key":"3110_CR27","first-page":"2132","volume":"93","author":"P Porcu","year":"1998","unstructured":"Porcu P, Neiman R, Orazi A (1998) Splenectomy in agnogenic myeloid metaplasia. Blood 93:2132\u20132134","journal-title":"Blood"},{"key":"3110_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129:667\u2013679. https:\/\/doi.org\/10.1182\/blood-2016-10-695940","journal-title":"Blood"},{"key":"3110_CR29","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1172\/JCI64397","volume":"122","author":"X Wang","year":"2012","unstructured":"Wang X, Prakash S, Lu M, Tripdo J, Ye F, Najfeld V, Li Y, Schwartz M, Weinberg R, Roda P, Orazi A, Hoffman R (2012) Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest 122:3888\u20133899. https:\/\/doi.org\/10.1172\/JCI64397","journal-title":"J Clin Invest"},{"key":"3110_CR30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson C, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A (2018) MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol 36:310\u2013318. https:\/\/doi.org\/10.1200\/JCO.2017.76.4886","journal-title":"J Clin Oncol"},{"key":"3110_CR31","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O\u2019Neil L, O\u2019Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ (2018) Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med 379:1416\u20131430. https:\/\/doi.org\/10.1056\/NEJMoa1716614","journal-title":"N Engl J Med"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-021-03110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-021-03110-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-021-03110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T15:06:38Z","timestamp":1634223998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-021-03110-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["3110"],"URL":"https:\/\/doi.org\/10.1007\/s00428-021-03110-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"26 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the University Hospital of Bordeaux (GP-CE2020-37).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients consented to the use of their specimens for research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}